CTCF Cooperates with Noncoding RNA MYCNOS to Promote Neuroblastoma Progression Through Facilitating MYCN Expression
Overview
Affiliations
Previous studies have indicated the important roles of MYCN in tumorigenesis and progression of neuroblastoma (NB), the most common extracranial solid tumor derived from neural crest in childhood. However, the regulatory mechanisms of MYCN expression in NB still remain largely unknown. In this study, through mining public microarray databases and analyzing the cis-regulatory elements and chromatin immunoprecipitation data sets, we identified CCCTC-binding factor (CTCF) as a crucial transcription factor facilitating the MYCN expression in NB. RNA immunoprecipitation, RNA electrophoretic mobility shift assay, RNA pull down and in vitro binding assay indicated the physical interaction between CTCF and MYCN opposite strand (MYCNOS), a natural noncoding RNA surrounding the MYNC promoter. Gain- and loss-of-function studies revealed that MYCNOS facilitated the recruitment of CTCF to its binding sites within the MYCN promoter to induce chromatin remodeling, resulting in enhanced MYCN levels and altered downstream gene expression, in cultured NB cell lines. CTCF cooperated with MYCNOS to suppress the differentiation and promote the growth, invasion and metastasis of NB cells in vitro and in vivo. In clinical NB tissues and cell lines, CTCF and MYCNOS were upregulated and positively correlated with MYCN expression. CTCF was an independent prognostic factor for unfavorable outcome of NB, and patients with high MYCNOS expression had lower survival probability. Taken together, these results demonstrate that CTCF cooperates with noncoding RNA MYCNOS to exhibit oncogenic activity that affects the aggressiveness and progression of NB through transcriptional upregulation of MYCN.
Yang C, Qu J, Cheng Y, Tian M, Wang Z, Wang X J Transl Med. 2024; 22(1):1153.
PMID: 39731187 PMC: 11673900. DOI: 10.1186/s12967-024-05956-4.
Niu Y, Tang Y, Ma F, Zhou X, Chen Y, Wang Y Oncogene. 2024; 44(4):255-268.
PMID: 39511411 PMC: 11746145. DOI: 10.1038/s41388-024-03202-1.
Talebi E, Ghoraeian P, Shams Z, Rahimi H Ann Hematol. 2024; 103(12):5439-5447.
PMID: 39223285 DOI: 10.1007/s00277-024-05763-3.
Guo F, Du N, Wen X, Li Z, Guo Y, Zhou L Cell Mol Life Sci. 2024; 81(1):307.
PMID: 39048814 PMC: 11335232. DOI: 10.1007/s00018-024-05285-1.
RPL35A drives ovarian cancer progression by promoting the binding of YY1 to CTCF promoter.
Wu H, Xia L, Sun L, Li D, Liu X, Song H J Cell Mol Med. 2024; 28(6):e18115.
PMID: 38436544 PMC: 10910871. DOI: 10.1111/jcmm.18115.